Ginkgo Bioworks (DNA) Regains NYSE Compliance

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that it had received a letter from the New York Stock Exchange ("NYSE") on September 3, 2024 stating that because Ginkgo's Class A common stock had a closing bid price at or above $1.00 on the last day of August and the Company's 30-day trading average closed above $1.00, Ginkgo had regained compliance with Section 802.01C of the NYSE Listed Company Manual.

As previously disclosed, Ginkgo was notified on May 7, 2024 that its Class A common stock failed to maintain a minimum average closing price that was above $1.00 per share over a consecutive 30 trading-day period, as required by the NYSE Listed Company Manual. Following a 1-for-40 reverse stock split, the Class A common stock opened for trading on the NYSE on a split adjusted basis on August 20, 2024.

Coinciding with the notification of Ginkgo's Class A common stock compliance, Ginkgo also received notice from NYSE on September 3, 2024 that it will commence proceedings to delist the Company's public warrants which were previously issued in connection with Soaring Eagle Acquisition Corp's initial public offering (the "Warrants"). These Warrants will be immediately suspended from trading due to "abnormally low" trading price levels pursuant to 802.01D of the NYSE Listed Company Manual. Trading in the Ginkgo's Class A Common Stock will be unaffected and will continue on the NYSE under the symbol "DNA".

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Critical One Energy closes second tranche of flow-through placement
• Home Depot (HD) call put ratio 1.5 calls to 1 put with a focus on September 330 puts into quarter results